share_log

Pyxis Oncology (NASDAQ:PYXS) Given Outperform Rating at Lifesci Capital

Pyxis Oncology (NASDAQ:PYXS) Given Outperform Rating at Lifesci Capital

Pyxis 腫瘤科（NASDAQ：PYXS）在生命資本中給予「表現優越」評級
kopsource ·  2022/12/03 08:21

Lifesci Capital restated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS – Get Rating) in a research note released on Thursday morning, PriceTargets.com reports.

生命資本重申其對股份的表現超越評級 皮西斯腫瘤科 (納斯達克:PYXS — 獲得評分) 在星期四早上發布的一份研究報告中，Pricetargets.com 報導。

Pyxis Oncology Stock Down 4.5 %

派西斯腫瘤學股票下跌 4.5%

Shares of PYXS stock opened at $1.39 on Thursday. The business's fifty day simple moving average is $1.65 and its 200-day simple moving average is $2.25. Pyxis Oncology has a 12-month low of $1.34 and a 12-month high of $12.38.

PYXS 股票的股票在周四 1.39 美元開盤。該企業的五十天簡單移動平均線為 1.65 美元，其 200 天的簡單移動平均線為 2.25 美元。吡蟲腫瘤科有 12 個月低點為 1.34 美元，為 12 個月高點 12.38 美元。

Get
取得
Pyxis Oncology
派西斯腫瘤科
alerts:
警報：

Pyxis Oncology (NASDAQ:PYXS – Get Rating) last issued its quarterly earnings results on Tuesday, November 1st. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.09). As a group, research analysts forecast that Pyxis Oncology will post -3.64 earnings per share for the current year.

Pyxis 腫瘤科 (NASDAQ: PYXS — 獲得評級) 上次公佈其季度盈利業績日期為 11 月 1 日（星期二）。該公司報告了本季每股盈利（0.85 美元），缺少分析師的共識估計為（0.76 美元）（0.09 美元）。作為一個小組，研究分析師預測，Pyxis 腫瘤科技將公佈本年度每股盈利 -3.64。

Hedge Funds Weigh In On Pyxis Oncology

對沖基金權衡 Pyxis 腫瘤學

A number of large investors have recently made changes to their positions in the business. Tang Capital Management LLC increased its position in shares of Pyxis Oncology by 2.4% during the third quarter. Tang Capital Management LLC now owns 1,411,569 shares of the company's stock worth $2,781,000 after purchasing an additional 32,489 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Pyxis Oncology by 8.0% in the 3rd quarter. Vanguard Group Inc. now owns 917,384 shares of the company's stock valued at $1,807,000 after acquiring an additional 68,304 shares during the period. Citadel Advisors LLC increased its position in shares of Pyxis Oncology by 0.6% in the 3rd quarter. Citadel Advisors LLC now owns 1,530,785 shares of the company's stock valued at $3,015,000 after acquiring an additional 9,849 shares during the period. Renaissance Technologies LLC increased its position in shares of Pyxis Oncology by 70.9% in the 3rd quarter. Renaissance Technologies LLC now owns 128,802 shares of the company's stock valued at $254,000 after acquiring an additional 53,431 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in shares of Pyxis Oncology by 414.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 15,736 shares of the company's stock valued at $31,000 after acquiring an additional 12,676 shares during the period. 71.59% of the stock is owned by institutional investors and hedge funds.
一些大型投資者最近更改了他們在業務中的頭寸。唐資本管理有限責任公司在第三季度增加了其在 Pyxis 腫瘤學股份的地位 2.4％。唐資本管理有限責任公司在上一季度額外購買 32,489 股股票後，擁有該公司股票的 1,411,569 股價值 2,781,000 美元。領航集團股份有限公司在第三季度增加了 8.0％ 在 Pyxis 腫瘤學的股份地位。領航集團股份有限公司在期內額外收購 68,304 股股份後，擁有該公司股票價值為 1,807,000 美元的 917,384 股股份。城堡顧問有限責任公司在第三季度增加了其在 Pyxis 腫瘤學股份的地位 0.6%。城堡顧問有限責任公司現在擁有該公司股票的 1,530,785 股，價值為 3,015,000 美元，在此期間額外獲得 9,849 股後。文藝復興科技有限責任公司在第三季度增加了 70.9％ 在 Pyxis 腫瘤的股份中的地位。文藝復興科技有限責任公司現在擁有該公司的 128,802 股股票，價值為 254,000 美元，在此期間另外收購 53,431 股股票後。最後，塔研究資本有限責任公司 TRC 在第三季度增加了 414.2％ 在 Pyxis 腫瘤的股份中的地位。在此期間，塔研究資本有限責任公司 TRC 現在擁有該公司股票的 15,736 股，價值 31,000 美元，價值 31,000 美元。71.59％ 的股票由機構投資者和對沖基金擁有。

Pyxis Oncology Company Profile

普賽斯腫瘤科公司簡介

(Get Rating)

(取得評分)

Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.

Pyxis Oncology, Inc 是一家臨床前生物製藥公司，致力於治療癌症的療法的開發。其免疫腫瘤產品候選產品包括 PYX-106，一種用於治療甲狀腺癌、頭頸鱗狀細胞癌、非小細胞肺癌（NSCLC）和其他實體腫瘤的研究性全人類免疫球蛋白 G1；以及 PYX-102（一種用於治療實體腫瘤的研究免疫治療）。

Read More

閱讀更多

  • Get a free copy of the StockNews.com research report on Pyxis Oncology (PYXS)
  • Why CSL Ltd Stock Could Be Worth a Look
  • MarketBeat: Week in Review 11/28 – 12/02
  • Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
  • Institutions Are Buying Ambarella, Should You?
  • Can ZIM Defy Broad Downturn In The Container Shipping Industry?
  • 獲取有關普西腫瘤科研究報告的免費副本
  • 為什麼 CSL 有限公司股票值得一看
  • 市場節拍：評論中的一周
  • Okta Inc 慶祝盈利節拍，但他們可以維持提升嗎？
  • 機構正在購買安巴雷拉，你應該嗎？
  • ZIM 能否抗拒集裝箱航運行業的廣泛低迷？

Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

接收有關 Pyxis 腫瘤日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 Pyxis 腫瘤學和相關公司的最新新聞和分析師評級的簡要每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論